Call for Abstract
9th International Conference and Expo on Molecular & Cancer Biomarkers, will be organized around the theme “ Labs to markets”
World Biomarkers 2017 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in World Biomarkers 2017
Submit your abstract to any of the mentioned tracks.
Register now for the conference by choosing an appropriate package suitable to you.
A biomarker can be anything that can be accurately measured as an indicator of normal biological functioning, pathogenic paths or a drug response to a therapeutic drug intervention. Biomarkers are the biomarker usually in molecular form. Biomarkers take part in various purposes, including disease diagnosis and prognosis, prediction and calculation of treatment response, and safety evaluation. The molecular biomarkers are exclusively being developed and validated to be used in drug development, and used to support approval of drug products.
- Track 1-1Protein biomarkers
- Track 1-2Nucleic acid based biomarkers
- Track 1-3Lipid biomarkers
- Track 1-4Small molecule biomarkers
A cancer biomarker is an element or procedure that indicates the presence of cancer in the body. A biomarker may be any molecule released by presence a tumor or a specific indication of the body to the presence of cancer. Cancer biomarkers are usually biological molecules found in blood, other body fluids, or tissues that are a sign of a normal or abnormal process, or of a condition or disease.
- Track 2-1Genetic biomarkers
- Track 2-2Pathological biomarkers
- Track 2-3In silico biomarkers
- Track 2-4Imaging biomarkers
- Track 2-5Glycoprotein biomarkers
Biomarkers which are used for clinical purposes are called clinical biomarkers. Clinical biomarkers along with Pathological biomarkers provide a vibrant and influential methodology to understanding the range of many diseases with uses in judgemental and analytic epidemiology, arbitrary clinical trials, screening for drugs or disease diagnosis and prognosis. Defined as changes in the constituents of cells or body fluids, these clinical biomarkers offer the means for standardized classification of a disease and risk factors, and the can extend the base information about the underlying pathogenesis of disease.
- Track 3-1Clinical biomarkers in drug discovery
- Track 3-2Clinical biomarkers in oncology
- Track 3-3Clinical biomarkers and pharmacogenomics
- Track 3-4Clinical biomarkers in diagnostics
Biomarkers play a significant role in cancer prognosis, diagnosis and treatment of cancers these days. There are many types of cancers which are hard to even diagnose. The latest designed biomarkers and their applications provide a great advantage in these cases. Cancer Epidemiology, treatment and latest research is greatly relayed on the biomarkers.
- Track 4-1Biomarkers for breast cancer
- Track 4-2Biomarkers for lung cancer
- Track 4-3Biomarkers for prostate cancer
- Track 4-4Biomarkers for blood cancer
- Track 4-5Biomarkers for adrenal cancer
- Track 4-6Biomarkers for colorectal cancer
- Track 4-7Biomarkers for gastric cancer
Biomarkers plan an important role in various neurological and cardiovascular diseases. The diseases which are incurable from ages are being offered a possible treatment and easy diagnosis with the help of advancements in biomarkers through different diagnostics and imaging technologies. Cardiac biomarkers and neuro biomarkers has brought a great revolution in disease diagnosis and prognosis.
- Track 5-1Biomarkers for Alzheimer’s
- Track 5-2Biomarkers for Cardiovascular diseases
- Track 5-3Biomarkers for Neurodegenerative diseases
- Track 5-4Biomarkers for diabetes
- Track 5-5Biomarkers for Huntington s disease
- Track 5-6Biomarkers for Behcet s disease
Even though radiological sciences have long history in the medical field, Imaging Biomarkers have given it a new turn. In the modern day radiology, biomarkers have an undividable integral part which has become the major reason for the latest developments in this field. This biomarker conference places a special session to focus on this area of research.
Circulating biomarkers allow for the possibility of early, non-invasive detection of cancers. They also represent highly sensitive biomarkers of submissive disease and are capable of reflecting tumour affliction and cancer changing aspects. In the cancer biomarkers conferences, clinical, technical, and biological aspects of cell free biomarkers, and new technologies and techniques will be discussed. Special attention will be given to studies on clinical cases to further see the sights of the applications of these biomarkers and prospective of cell free biomarkers in disease diagnostics.
- Track 7-1Latest techniques
- Track 7-2Technology to capture and characterize
- Track 7-3Patient management
- Track 7-4Targeted delivery
Cancer biomarkers have become an indispensable part of cancer patient care. With discovery efforts on-going, the next phase towards conversion will involve validation and verification of clinical value. This includes the steps needed to manage the new treatment model from treating clinical symptoms to targeting genomic pathways. Focus will be given to the use of circulating tumour material to follow patients peripherally, both with known metastatic disease and post-surgery. In these Molecular Biomarkers conferences a special importance is given to this field.
- Track 8-1Identifying and prioritizing biomarkers
- Track 8-2Circulating biomarkers
- Track 8-3Patient stratification using NGS data
- Track 8-4Challenges and solutions for NGS labs
Biomarker discovery requires highly assured identification of a biomarker with real-time quantitative information to indicate which proteins are altering to a statistically pertinent degree in response to disease. The discovery of biomarkers has developed new strategies starting from the initial steps. In the first stage of biomarker discovery proceedings, investigation depends upon mass spectrometry techniques to make unbiased, semiquantitative analysis of changes between healthy and diseased states. The slope of probable biomarkers generated in the discovery stage is to be further substantiated due to the high false positive rate. It is done through supplemental more targeted and quantitative mass spectrometry techniques, such as immuno affinity peptide enrichment.
- Track 9-1New strategies for discovery
- Track 9-2Protein biomarker discovery
- Track 9-3Clinical biomarker advances
- Track 9-4Biomarkers for paediatric diseases
- Track 9-5Clinical analysis of NGS samples
- Track 9-6Mass spectrometry based biomarker discovery
The probable Molecular Biomarkers identified in discovery section need to be validated by using larger sample sets casing a broad section of patient troops. To avoid a potential bottleneck associated with taking a large number of candidates to validation, a verification step is engaged to monitor potential molecular biomarkers to ensure that only the top quality biomarkers from the discovery phase are taken into the expensive validation stage. A high throughput workflow with a minimum of sample preparation is required in the verification stage which provides both high specificity and high sensitivity. Furthermore, the confirmation that a particular methodology is suitable to be used in the biomarker validation phase is given in verification stage. These advanced strategies can be sited at molecular biomarkers conference.
- Track 11-1Omics Technologies in Biomarkers Discovery and Validation
- Track 11-2Assessment of drug response
- Track 11-3Latest diagnosis techniques
- Track 11-4Application of tools
- Track 11-5Advancements in analysis
Biomarker testing is a group of tests that looks for the molecular signs of health so that doctors can plan the best care. Biomarker testing can also be called as genetic testing or molecular testing. Molecular biomarkers, a foundation of precision oncology, are very important in management of breast cancer, gastro-esophageal cancer and non-small cell lung cancer. Testing practices are intensely deliberated, influencing diagnostic quality and affecting pathologists, oncologists and patients.
- Track 12-1Genetic testing and Molecular Biomarkers
- Track 12-2Biomarker testing for cancers
- Track 12-3Biomarker testing for other diseases
- Track 12-4Biomarker testing in diagnosis
The ability to look at a patient individually will provide a more precise cancer diagnosis and specific treatment plan. The genetic information from individuals can then be used to effectively treat them, by finding the variations that can account for possible diseases. An individual’s genetic make-up also plays a large part in their extent of response to a certain treatment, and hence, having the knowledge of their genetic content can alter the type of treatment they receive. These approaches are intended to identify individualized patient benefits of therapies, minimize the risk of toxicity and reduce the cost of treatment.
- Track 13-1Diagnostic and prognostic biomarkers
- Track 13-2Tumor biomarkers
- Track 13-3Diagnosis and intervention
- Track 13-4Drug development and usage
- Track 13-5Cancer genomics
- Track 13-6Challenges and probable solutions
A medical device, which is often an in vitro device and which offers information that is important for the safe and operative use of a respective drug administration or biological product is called a companion diagnostic. These devices help to determine whether a specific therapeutic product’s benefits to a patient will be of more importance that can overshadow any possible serious side effects or risks to treat a patient. These molecular biomarkers conferences invite the latest technologies and techniques to be brought into light.
- Track 14-1In vitro companion diagnostics devices
- Track 14-2Medical devices
- Track 14-3Commercialization of companion diagnostics
- Track 14-4Strategies for Rx-Dx partnerships
- Track 14-5Choosing a platform for companion diagnostics
In the biomarker pipeline, the technologies that will enable the use of biomarkers in drug discovery and development vary depending on the research stage. The second stage, biomarker validation and clinical assay development, depends upon extremely sensitive and specific high-throughput immunoassays. The single greatest challenge in discovering biomarkers with clinical utility is the sensitivity and specificity necessary to determine that a biomarker is truly positive for disease or disease toxicodynamics, and can be used to detect deviations from normal. The molecular biomarkers conferences provide good exposure in drug discovery.
- Track 15-1Exploratory medicine
- Track 15-2Pharmacokinetic-Pharmacodynamic Modeling
- Track 15-3Biomarkers in translational medicine
- Track 15-4Biomarker utility in clinical development
- Track 15-5Safety assessment
The study of cancer is called Oncology. An oncologist is a person who specializes in the area of oncology and treating cancer patients. An oncologist manages care and treatment once a person is diagnosed with cancer.
- Track 16-1Oncologists in Germany
- Track 16-2Oncologists in USA
- Track 16-3Oncologists in Europe
- Track 16-4Oncologists in Asia
- Track 17-1Case reports on molecular biomarkers
- Track 17-2Case reports on cancer biomarkers
- Track 17-3Case reports on diagnostics
- Track 17-4Case reports on drug discover
- Track 17-5Case reports on imaging
Biomarkers Imaging is a cross-discipline which is an intersection of in vivo imaging and molecular biology. It facilitates the picturing of the cellular function and the supplement of the molecular process in biological processes without disturbing the living organisms. The various fields of study the Biomarkers Imaging brings life into are diagnosis of diseases such as cancer, cardiovascular diseases and neurological disorders. This technique also donates to the improvisation of the treatment of various diseases and disorders by adjusting the pre-clinical and clinical tests of new drugs. The biomarkers dynamics meetings are also expected to have a major economic impact due to very prior and more precise diagnosis.
- Track 18-1Imaging Biomarkers
- Track 18-2Clinical imaging and Biomarkers
- Track 18-3Fluorescent biomarkers
- Track 18-4Cancer screening
- Track 18-5Screening for other diseases
- Track 18-6New generation tools and technologies
Self-knowledge is the key ingredient in successful entrepreneurship. Molecular Biomarkers conferences aim to bring together all existing and promising bio entrepreneurs to share capabilities and present new novelties and challenges in biomarker community. Over a million companies are started in the world each year, in which about 5–10 of them are classified into high technology companies. All the Pharmaceutical and Biotech companies are majorly involved in the biomarkers production. Whirling ideas into business ventures is complex and the opportunity appreciation step is critical in new project creation. This idea in the entrepreneur's perception of the association between the invention and final product is converted into a business prototype that describes how the venture generate revenue or provide an suitable yield to the prospective investors. Clinical Research on biomarkers is multifaceted and rapidly expanding and requires an expert knowledge to comprehend the value of the advances and its competitive situation in the industry. Even though scientists are stereotypically the founders of biotech companies, studies indicate that the most effective start-ups are founded by a team which often has two to three individuals with mixed backgrounds like clinical research and Clinical Data Management along with considerable industry experience and a very strong market and product focus at establishment.